glp-1 china Novo Nordisk's diet drug may land in soon The Evolution of GLP-1 Drugs
Description
How Soon Will You See Results
A regulatory filing in type 2 diabetes is expected in 2026
Health claim ID 3988 pending European approval
A non-injectable, non-stimulant alternative to GLP-1 drugs
These facts, together with increasing comorbidities in patients with IBD, imply that urgent, more complex, novel therapeutic strategies in the treatment are needed
